Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: Two randomized, controlled trials

Anemia

Volumn 2012, Issue , 2012, Pages

  Barish, Charles F ^a   Koch, Todd ^b   Butcher, Angelia ^b   Morris, David ^c   Bregman, David B ^b,d  

^a WAKE RESEARCH ASSOCIATES   (United States)

^b Luitpold Pharmaceuticals Inc   (United States)

^c WebbWrites LLC   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873861354     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2012/172104     Document Type: Article

References (30)

1. Killip S., Bennett J. M., Chambers M. D., Iron deficiency anemia. American Family Physician 2007 75 5 671 678 2-s2.0-33947145567 (Pubitemid 46397884)
2. Umbreit J., Iron deficiency: a concise review. American Journal of Hematology 2005 78 3 225 231 2-s2.0-14644389345 10.1002/ajh.20249 (Pubitemid 40316503)
3. Gisbert J. P., Gomollón F., Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. American Journal of Gastroenterology 2008 103 5 1299 1307 2-s2.0-43549115913 10.1111/j.1572-0241. 2008.01846.x (Pubitemid 351678000)
4. Haas J. D., Brownlie T. T., Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. Journal of Nutrition 2001 131 2 676S 690S 2-s2.0-0035150473 (Pubitemid 32115345)
5. Horton S., Levin C., Commentary on 'evidence that iron deficiency anemia causes reduced work capacity'. Journal of Nutrition 2001 131 2 691S 696S 2-s2.0-0035156195 (Pubitemid 32115346)
6. Gisbert J. P., Bermejo F., Pajares R., Pérez-Calle J. L., Rodríguez M., Algaba A., Mancenido N., De La Morena F., Carneros J. A., McNicholl A. G., González-Lama Y., Maté J., Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflammatory Bowel Diseases 2009 15 10 1485 1491 2-s2.0-70349277116 10.1002/ibd.20925
7. Henry D. H., The role of intravenous iron in cancer-related anemia. Oncology 2006 20 8 21 24 2-s2.0-33846959607
8. Goddard A. F., James M. W., McIntyre A. S., Scott B. B., Guidelines for the management of iron deficiency anaemia. Gut 2011 60 309 1316 2-s2.0-79955752351 10.1136/gut.2010.228874
9. KDOQI, National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. American Journal of Kidney Diseases 2006 47 5, supplement 3 S16 S85
10. Gotloib L., Silverberg D., Fudin R., Shostak A., Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. Journal of Nephrology 2006 19 2 161 167 2-s2.0-33748861418 (Pubitemid 44420105)
11. Qunibi W. Y., The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittel-Forschung 2010 60 6 a 399 412 2-s2.0-77956806828
12. Rosner M. H., Auerbach M., Ferumoxytol for the treatment of iron deficiency. Expert Review of Hematology 2011 4 4 399 406 2-s2.0-79961040926 10.1586/ehm.11.31
13. Santosh S., Podaralla P., Miller B., Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. NDT Plus 2010 3 4 341 342 2-s2.0-77956028834 10.1093/ndtplus/sfq084
14. Lyseng-Williamson K. A., Keating G. M., Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009 69 6 739 756 2-s2.0-65949107825 10.2165/00003495-200969060-00007
15. Geisser P., Banké-Bochita J., Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittel-Forschung 2010 60 6 a 362 372 2-s2.0-77956857469
16. Geisser P., Rumyantsev V., Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittel-Forschung 2010 60 6 a 373 385 2-s2.0-77956802593
17. Funk F., Ryle P., Canclini C., Neiser S., Geisser P., The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittel-Forschung 2010 60 6 a 345 353 2-s2.0-77956860272
18. Moore R. A., Gaskell H., Rose P., Allan J., Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders 2011 11 1, article 4
19. Kulnigg S., Stoinov S., Simanenkov V., Dudar L. V., Karnafel W., Garcia L. C., Sambuelli A. M., D'Haens G., Gasche C., A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology 2008 103 5 1182 1192 2-s2.0-43549093318 10.1111/j.1572-0241. 2007.01744.x (Pubitemid 351677967)
20. Qunibi W. Y., Martinez C., Smith M., Benjamin J., Mangione A., Roger S. D., A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis- dependent chronic kidney disease patients. Nephrology Dialysis Transplantation 2011 26 5 1599 1607 2-s2.0-79955586213 10.1093/ndt/gfq613
21. Tagboto S., Cropper L., Turner J., Pugh-Clarke K., The efficicacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Journal of Renal Care 2009 35 1 18 23 2-s2.0-61849169432 10.1111/j.1755-6686.2009.00075.x
22. Van Wyck D. B., Mangione A., Morrison J., Hadley P. E., Jehle J. A., Goodnough L. T., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009 49 12 2719 2728 2-s2.0-71849101678 10.1111/j.1537-2995.2009. 02327.x
23. Van Wyck D. B., Martens M. G., Seid M. H., Baker J. B., Mangione A., Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstetrics and Gynecology 2007 110 2 I 267 278 2-s2.0-34548462994 10.1097/01.AOG.0000275286.03283.18 (Pubitemid 47356650)
24. Anker S. D., Colet J. C., Filippatos G., Willenheimer R., Dickstein K., Drexler H., Lüscher T. F., Bart B., Banasiak W., Niegowska J., Kirwan B. A., Mori C., Von Eisenhart Rothe B. E., Pocock S. J., Poole-Wilson P. A., Ponikowski P., Ferric carboxymaltose in patients with heart failure and iron deficiency. The New England Journal of Medicine 2009 361 25 2436 2448 2-s2.0-72449156527 10.1056/NEJMoa0908355
25. Wilson P. W. F., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B., Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 18 1837 1847 2-s2.0-0032510639 (Pubitemid 28213628)
26. Arroliga A. C., Guntupalli K. K., Beaver J. S., Langholff W., Marino K., Kelly K., Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Critical Care Medicine 2009 37 4 1299 1307 2-s2.0-67650492404 10.1097/CCM. 0b013e31819cec94
27. Shimizu Y., Tada Y., Yamauchi M., Okamoto T., Suzuki H., Ito N., Fukumoto S., Sugimoto T., Fujita T., Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia. Bone 2009 45 4 814 816 2-s2.0-68849127439 10.1016/j.bone.2009. 06.017
28. Schouten B. J., Hunt P. J., Livesey J. H., Frampton C. M., Soule S. G., FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. Journal of Clinical Endocrinology and Metabolism 2009 94 7 2332 2337 2-s2.0-67650215157 10.1210/jc.2008-2396
29. Mani L. Y., Nseir G., Venetz J. P., Pascual M., Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010 90 7 804 805 2-s2.0-77958003055 10.1097/TP.0b013e3181f00a18
30. Grimmelt A. C., Cohen C. D., Fehr T., Serra A. L., Wüthrich R. P., Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clinical Nephrology 2009 71 2 125 129 2-s2.0-64549090727